Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Double Blind Placebo Controlled Trial to Assess Safety and Efficacy of Velafermin for Prevention of Oral Mucositis in Hematologic Cancer Patients Receiving Autologous Stem Cell Transplant

NCT00323518 is registered in ClinicalTrials.gov with CuraGen Corporation as lead sponsor.

NCT NCT00323518
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00323518 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Double Blind Placebo Controlled Trial to Assess Safety and Efficacy of Velafermin for Prevention of Oral Mucositis in Hematologic Cancer Patients Receiving Autologous Stem Cell Transplant
Lead sponsor
CuraGen Corporation
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2006
Completion date
August 31, 2008
Enrollment
390 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

oral mucositis, stomatitis